drugset

drugset / Trial / NCT07579910

Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB

NCT07579910 ↗

Phase 3 Not yet recruiting 14 enrolled Spruce Biosciences

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition

Timeline

Start: 2026-12
Primary completion: 2033-08
Completion: 2033-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AX 250	Protein / enzyme biologic	—	Other

Indications